Table 2.
CAR T therapeutic products approved for commercial use
| Trade name | Co-stimulatory domain | Target | Indication | Dose level (cells) | Clinical efficacy | Clinical Trial |
|---|---|---|---|---|---|---|
| Kymriah | 4-1BB | CD19 | R/R ALL (≤ 25 years of age) | 3.1 × 106/kg | ORR: 81% CRR: 60% | NCT02435849 |
| R/R LBCL | 3 × 108 | ORR: 52% CRR: 40% | NCT02445248 | |||
| R/R FL | 2.06 × 108 | ORR: 86% CRR: 69% | NCT03568461 | |||
| Yescarta | CD28 | CD19 | R/R LBCL | 2 × 106/kg | ORR: 82% CRR: 54% | NCT02348216 |
| R/R FL | 2 × 106/kg | ORR: 94% CRR: 79% | NCT03105336 | |||
| Tecartus | CD28 | CD19 | MCL | 2 × 106/kg | ORR: 91% CRR: 68% | NCT02601313 |
| ALL | 1 × 106/kg | ORR: NR CRR: 71% | NCT02614066 | |||
| Breyanzi | 4-1BB | CD19 | LBCL |
50 × 106 100 × 106 150 × 106 |
ORR:68% CRR:60% ORR:74% CRR:52% ORR:73% CRR:51% |
NCT02631044 |
| Abecma | 4-1BB | BCMA | R/R MM |
150 × 106 300 × 106 450 × 106 |
ORR:50% CRR:25% ORR:69% CRR:29% ORR:81% CRR:39% |
NCT03361748 |
| Carvykti | 4-1BB | BCMA | R/R MM | 0.75 × 106/kg | ORR:98% CRR:83% | NCT03548207 |
| JWCAR029 | 4-1BB | CD19 | R/R LBCL | 100 × 106 or 150 × 106 | ORR:76% CRR:52% | NCT04089215 |
R/R, relapsed/refractory; ALL, acute lymphoblastic leukemia; LBCL, large B-cell lymphoma; FL, follicular lymphoma; MCL, mantle cell lymphoma; MM, multiple myeloma; ORR, objective response rate; CRR, complete response rate; NR, not reported